Navigation Links
MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

GAITHERSBURG, Md., Oct. 23 /PRNewswire/ -- MedImmune today announced that researchers will present eight posters from its inflammatory disease program at the Annual Meeting of the American College of Rheumatology, from October 24 to 29, 2008 at the Moscone Center in San Francisco, California.

"MedImmune is working on a number of potential solutions for patients struggling with systemic autoimmune rheumatic diseases," said Barbara White, M.D., vice president, clinical development, respiratory, inflammation, and autoimmunity. "We are pleased to share promising basic research and translational science data relevant to the development of new treatments for diseases such as lupus, rheumatoid arthritis, and myositis"

MedImmune programs that will be discussed include:

-- MEDI-545 - MEDI-545 is a monoclonal antibody (MAb) targeting

interferon-alpha, which regulates processes involved in autoimmune

diseases. MedImmune has launched a broad development program with this

molecule to assess its potential to treat or prevent a variety of

immunological disorders. Currently, MedImmune is conducting a phase 2a

trial in patients with systemic lupus erythematosus (SLE) and a phase 1b

study in patients with active dermatomyositis and polymyositis. The

company has also conducted clinical trials in psoriasis with MEDI-545.

-- CAM-3001 - CAM-3001 is a MAb with potential to help patients with

rheumatoid arthritis. The antibody targets the alpha sub-unit of the

granulocyte-macrophage colony stimulating factor receptor (GM-CSFR).

CAM-3001 is a phase 1 clinical stage program.

-- ICOS - ICOS (Inducible costimulator) is a receptor on activated T-cells

that plays a central role in humoral immunity. Elevated levels of ICOS

are present in patients with autoimmune diseases and effector cytokines

have been shown to correlate with increased levels of this protein.

MedImmune has a preclinical program studying the over-expression of ICOS

in several autoimmune diseases.

-- CXCL13 - CXCL13 is a molecule that recruits B cells into inflammatory

cell aggregates called follicles. In patients with rheumatoid arthritis

the levels of CXCL13 are elevated within the inflamed joints thus

encouraging B cells to accumulate and interact with a range of cells,

such as T cells, within the joint promoting the generation of new

inflammatory follicles and contributing to the disease process.

MedImmune has a preclinical program investigating antibodies that target CXCL13 which may have the potential to prevent the generation of these inflammatory follicles within the rheumatic joint.

The schedule for MedImmune's eight research posters to be presented at the meeting, starting on Sunday October 26, is as follows:

-- ICOS as a potential regulator in inclusion body myositis and

dermatomyositis - Chris Morehouse, M.Sc., Sunday, October 26 from 9:00

a.m. - 11:00 a.m. in Hall A, Abstract: 46

-- Internalization of the antibody (CAM-3001) following monocyte cell

surface binding to the GM-CSFR alpha chain - Brandon Higgs, Ph.D.,

Sunday, October 26 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 35

-- Neutralization of CXCL13 impacts B-cell trafficking and reduces severity

of established experimental arthritis - Matthew Sleeman, Ph.D., Monday,

October 27 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 771

-- IFN-alpha/beta as a therapeutic target in systemic lupus erythematosus,

myositis, and rheumatoid arthritis: a transcript profiling analysis of

whole blood from multiple autoimmune diseases - Brandon Higgs, Ph.D.,

Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract:


-- Neutralizing IFN-alpha in SLE affects GMCSF, TNF-alpha, IL-10, IL1-beta

and BAFF signaling pathways - Brandon Higgs, Ph.D., Tuesday, October 28

from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 1340

-- Memory T lymphocytes expressing the inducible costimulator (icos) are

required to maintain the secondary lymphoid tissue architecture in non

human primates - Gianluca Carlesso, Ph.D., Tuesday, October 28 from 9:00

a.m. - 11:00 a.m. in Hall A, Abstract: 1843

-- In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody

for the treatment of patients with rheumatoid arthritis - Matthew

Sleeman, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall

A, Abstract: 1338

-- Use of a SOCS3 ex-vivopharmacodynamic quantitative RT-PCR assay for

CAM-3001, a new antibody therapy for the treatment of rheumatoid

arthritis - Jo Woods, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00

a.m. in Hall A, Abstract: 1339

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
2. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
3. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
4. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
5. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
6. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
7. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
8. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
9. Seneca Valley High School Student Receives Science Award From MedImmune
10. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
Breaking Biology News(10 mins):